Biotech Values

[pcrutch]

Abstracts related to IMGN, MITI, CYTR and SGEN

MITI

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma
http://ash.confex.com/ash/2011/webprogram/Paper36931.html

IMGN

Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies
http://ash.confex.com/ash/2011/webprogram/Paper42689.html

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
http://ash.confex.com/ash/2011/webprogram/Paper42689.html

CYTR

A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia
http://ash.confex.com/ash/2011/webprogram/Paper37927.html

SGEN

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
http://ash.confex.com/ash/2011/webprogram/Paper41973.html

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
http://ash.confex.com/ash/2011/webprogram/Paper42557.html

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas
http://ash.confex.com/ash/2011/webprogram/Paper42494.html

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
http://ash.confex.com/ash/2011/webprogram/Paper42148.html

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
http://ash.confex.com/ash/2011/webprogram/Paper39211.html

===========

Nothing posted on SAR3419 or IMGN901